Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has maintained an Equal-Weight rating on Bicycle Therapeutics (NASDAQ:BCYC) but lowered the price target from $42 to $40.
November 03, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Bicycle Therapeutics but lowered the price target from $42 to $40.
The lowering of the price target by Morgan Stanley could potentially lead to a decrease in the stock price of Bicycle Therapeutics in the short term. This is because the new price target suggests that the analyst believes the stock is currently overvalued.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100